Tintoré M - Search Results

1

Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.

Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintoré M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Bass AD, et al. Among authors: tintore m. Mult Scler Relat Disord. 2021 Apr;49:102717. doi: 10.1016/j.msard.2020.102717. Epub 2020 Dec 24. Mult Scler Relat Disord. 2021. PMID: 33476880 Free article.

2

Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.

Nos C, Sastre-Garriga J, Borràs C, Río J, Tintoré M, Montalban X. Nos C, et al. Among authors: tintore m. Mult Scler. 2004 Aug;10(4):413-6. doi: 10.1191/1352458504ms1068oa. Mult Scler. 2004. PMID: 15327039

3

Early MS treatment.

Tintoré M. Tintoré M. Int MS J. 2007 Mar;14(1):5-10. Int MS J. 2007. PMID: 17509246 Review.

4

Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.

Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM. Kragt JJ, et al. Among authors: tintore m. Neurology. 2008 Mar 25;70(13 Pt 2):1084-91. doi: 10.1212/01.wnl.0000288179.86056.e1. Epub 2008 Jan 9. Neurology. 2008. PMID: 18184917

5

Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.

Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X. Río J, et al. Among authors: tintore m. Mult Scler. 2008 May;14(4):479-84. doi: 10.1177/1352458507085555. Mult Scler. 2008. PMID: 18562504 Clinical Trial.

6

Very early scans for demonstrating dissemination in time in multiple sclerosis.

Tur C, Tintoré M, Rovira A, Nos C, Río J, Téllez N, Galán I, Perkal H, Comabella M, Sastre-Garriga J, Montalban X. Tur C, et al. Among authors: tintore m. Mult Scler. 2008 Jun;14(5):631-5. doi: 10.1177/1352458507087327. Mult Scler. 2008. PMID: 18566026

7

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.

O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group. O'Connor P, et al. Neurology. 2009 Jan 6;72(1):73-9. doi: 10.1212/01.wnl.0000338569.32367.3d. Neurology. 2009. PMID: 19122034 Clinical Trial.

8

The search for responsive clinical endpoints in primary progressive multiple sclerosis.

Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintoré M, Uitdehaag BM. Bosma LV, et al. Among authors: tintore m. Mult Scler. 2009 Jun;15(6):715-20. doi: 10.1177/1352458509102626. Epub 2009 Apr 21. Mult Scler. 2009. PMID: 19383646

9

Measures in the first year of therapy predict the response to interferon beta in MS.

Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalbán X. Río J, et al. Among authors: tintore m. Mult Scler. 2009 Jul;15(7):848-53. doi: 10.1177/1352458509104591. Mult Scler. 2009. PMID: 19542263

10

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.

Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group. Comi G, et al. Mult Scler. 2010 Feb;16(2):197-207. doi: 10.1177/1352458509357065. Epub 2009 Dec 22. Mult Scler. 2010. PMID: 20028707 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

354 results

Search Page